Two-hour algorithm for rapid triage of suspected acute myocardial infarction using a high-sensitivity cardiac troponin I assay

Nestelberger, Thomas, Boeddinghaus, Jasper, , , Than, Martin, Wussler, Desiree, Lopez-Ayala, Pedro, Zimmermann, Tobias, Meier, Mario, Troester, Valentina, Badertscher, Patrick, Koechlin, Luca, Wildi, Karin, Anwar, Mahnoor, Freese, Michael, Keller, Dagmar I., Reichlin, Tobias, Twerenbold, Raphael, , Mueller, Christian, Puelacher, Christian, Du Fay De Lavallaz, Jeanne, Giménez, Maria Rubini, Strebel, Ivo, Walter, Joan, Huber, Jeffrey, Christ, Michael, Kozhuharov, Nikola, Gualandro, Danielle M., Potlukova, Eliska, Baumgartner, Benjamin, Hafner, Benjamin, Rent-Sch, Katharina, Miró, Òscar, Fuenzalida, Carolina, Gil, Beatriz, Javier Martin-Sanchez, F., Kawecki, Damian, Geigy, Nicolas, Meissner, Kathrin, Kulangara, Caroline, López, Beatriz, Adrada, Esther Rodriguez, Ganovská, Eva, Lohrmann, Jens, Kloos, Wanda, Steude, Jana, Buser, Andreas, Von Eckardstein, Arnold, Nowalany-Kozielska, Ewa, & Muzyk, Piotr (2019) Two-hour algorithm for rapid triage of suspected acute myocardial infarction using a high-sensitivity cardiac troponin I assay. Clinical Chemistry, 65(11), pp. 1437-1447.

Free-to-read version at publisher website

Description

BACKGROUND
We aimed to derive and externally validate a 0/2-h algorithm using the high-sensitivity cardiac troponin I (hs-cTnI)-Access assay.
METHODS
We enrolled patients presenting to the emergency department with symptoms suggestive of acute myocardial infarction (AMI) in 2 prospective diagnostic studies using central adjudication. Two independent cardiologists adjudicated the final diagnosis, including all available medical information including cardiac imaging. hs-cTnI-Access concentrations were measured at presentation and after 2 h in a blinded fashion.
RESULTS
AMI was the adjudicated final diagnosis in 164 of 1131 (14.5%) patients in the derivation cohort. Rule-out by the hs-cTnI-Access 0/2-h algorithm was defined as 0-h hs-cTnI-Access concentration <4 ng/L in patients with an onset of chest pain >3 h (direct rule-out) or a 0-h hs-cTnI-Access concentration <5 ng/L and an absolute change within 2 h <5 ng/L in all other patients. Derived thresholds for rule-in were a 0-h hs-cTnI-Access concentration ≥50 ng/L (direct rule-in) or an absolute change within 2 h ≥20 ng/L. In the derivation cohort, these cutoffs ruled out 55% of patients with a negative predictive value (NPV) of 99.8% (95% CI, 99.3–100) and sensitivity of 99.4% (95% CI, 96.5–99.9), and ruled in 30% of patients with a positive predictive value (PPV) of 73% (95% CI, 66.1–79). In the validation cohort, AMI was the adjudicated final diagnosis in 88 of 1280 (6.9%) patients. These cutoffs ruled out 77.9% of patients with an NPV of 99.8% (95% CI, 99.3–100) and sensitivity of 97.7% (95% CI, 92.0–99.7), and ruled in 5.8% of patients with a PPV of 77% (95% CI, 65.8–86) in the validation cohort.
CONCLUSIONS
Safety and efficacy of the l hs-cTnI-Access 0/2-h algorithm for triage toward rule-out or rule-in of AMI are very high.

Impact and interest:

38 citations in Scopus
24 citations in Web of Science®
Search Google Scholar™

Citation counts are sourced monthly from Scopus and Web of Science® citation databases.

These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.

Citations counts from the Google Scholar™ indexing service can be viewed at the linked Google Scholar™ search.

ID Code: 197677
Item Type: Contribution to Journal (Journal Article)
Refereed: Yes
ORCID iD:
Greenslade, Jaimiorcid.org/0000-0002-6970-5573
Parsonage, William A.orcid.org/0000-0002-0223-5378
Measurements or Duration: 11 pages
DOI: 10.1373/clinchem.2019.305193
ISSN: 0009-9147
Pure ID: 46535214
Divisions: Past > QUT Faculties & Divisions > Faculty of Health
Past > Institutes > Institute of Health and Biomedical Innovation
Funding Information: Employment or Leadership: None declared. Consultant or Advisory Role: T. Nestelberger, Beckman-Coulter and Ortho Clinical Diagnostics; J. Boeddinghaus, Siemens and Roche Diagnostics; W. Parsonage, Abbott; R. Twerenbold, Abbott, Amgen, Roche, Siemens, Singulex, Thermo Scientific, and BRAHMS; C. Mu-eller, Abbott, Alere, Astra Zeneca, Biomerieux, Boehringer Ingelheim, BMS, Brahms, Cardiorentis, Novartis, Roche, Siemens, and Singulex. Stock Ownership: None declared. Honoraria: T. Nestelberger, Beckman-Coulter and Ortho Clinical Diagnostics; J. Boeddinghaus, Siemens and Roche Diagnostics; W. Parsonage, Abbott; R. Twerenbold, Abbott, Amgen, Roche, Siemens, Sin-gulex, Thermo Scientific, and BRAHMS; C. Mueller, Abbott, Alere, Astra Zeneca, Biomerieux, Boehringer Ingelheim, BMS, Brahms, Car-diorentis, Novartis, Roche, Siemens, and Singulex. Research Funding: APACE was supported by research grants from the Swiss National Science Foundation, the Swiss Heart Foundation, the KTI, the European Union, the Stiftung für kardiovaskuläre Forschung Basel; Abbott, Beckman Coulter, Biomerieux, Brahms, Roche, Siemens, and Singulex. ADAPT was supported by research grants from the Emergency Medicine Foundation, the Royal Brisbane and Women’s Hospital Foundation and Beckman Coulter. The investigated hs-cTn assay reagents were donated by the manufacturers. J. Boeddinghaus, research grants from the University of Basel and the Division of Internal Medicine, the Swiss Academy of Medical Sciences, the Gottfried and Julia Bangerter-Rhyner-Foundation; J. Greenslade, funding from Emergency Medicine Foundation to institution; L.A. Cullen, grants from Beckman Coulter, Roche, and Abbott during the conduct of the study and grants from Roche, grants and personal fees from Abbott Diagnostics, grants from Siemens, grants from Radiometer, personal fees from AstraZeneca, grants from Alere outside the submitted work; R. Twerenbold, research support from the Swiss National Science Foundation (grant no. P300PB 167803), the Swiss Heart Foundation, the Swiss Society of Cardiology, the Cardiovascular Research Foundation Basel, the University of Basel, and the University Hospital Basel; P. Badertscher, research funding from the University of Basel, the “Stiftung für Herzschrittmacher und Elektrophysiologie,” and the “Freiwillige Akademische Gesellschaft Basel” outside the submitted work; L. Koechlin, research grant from the University of Basel, the Swiss Academy of Medical Sciences and the Gottfried and Julia Bangerter-Rhyner Foundation, the “Freiwillige Akademische Gesellschaft Basel”; C. Mueller, research support from the Swiss National Science Foundation, the Swiss Heart Foundation, the KTI, the Stiftung für kardiovaskuläre Forschung Basel; Abbott, Alere, Astra Zeneca, Beckman Coulter, Biomerieux, Brahms, Roche, Siemens, Singulex, Sphingotec, and the Department of Internal Medicine, University Hospital Basel. Expert Testimony: None declared. Patents: None declared. Other Remuneration: J. Boeddinghaus, Siemens Healthineers, Roche Diagnostics.
Copyright Owner: 2019 The American Association for Clinical Chemistry
Copyright Statement: This work is covered by copyright. Unless the document is being made available under a Creative Commons Licence, you must assume that re-use is limited to personal use and that permission from the copyright owner must be obtained for all other uses. If the document is available under a Creative Commons License (or other specified license) then refer to the Licence for details of permitted re-use. It is a condition of access that users recognise and abide by the legal requirements associated with these rights. If you believe that this work infringes copyright please provide details by email to qut.copyright@qut.edu.au
Deposited On: 17 Mar 2020 05:46
Last Modified: 03 Apr 2024 12:01